Gut‑bone metabolites: SCFAs, polyamines and microbial metabolomics in osteoporosis risk and therapy (Review)
International Journal of Molecular Medicine · 21.07.2026 · 58 (3) · 1-21
DOI: 10.3892/ijmm.2026.5934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 21.07.2026. Verfasst von Fuchao Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China. Hauptthemen laut MEDLINE: Osteoporosis, Polyamines, Bone and Bones, Gastrointestinal Microbiome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Osteoporosis (OP), a major global skeletal disorder characterized by reduced bone mass and increased fracture risk, is increasingly understood through the lens of the gut‑bone axis. The present review critically synthesizes mechanistic and translational evidence for two classes of gut microbial metabolites short‑chain fatty acids (SCFAs) and polyamines, as active regulators of bone remodeling. SCFAs (acetate, propionate and butyrate) suppress osteoclastogenesis via the TRAF6/NFATc1 pathway, promote osteoblast differentiation through GPR43/GPR109A signaling and histone deacetylase inhibition, and expand immuno‑protective regulatory T cells in the bone marrow. Microbial polyamines (spermidine, spermine and putrescine) promote osteogenesis by upregulating Runx2 and alkaline phosphatase and inhibit osteoclastogenesis through suppression of the Ca²+‑PYK2‑Src‑NFATc1 axis. Integrative multi‑omics analyses and Mendelian randomization studies provide causal evidence linking specific gut taxa, their metabolic outputs and OP risk. Distinct from prior reviews of the gut‑bone axis, the present review uniquely integrates microbial metabolomics platforms, eIF5A hypusination as a novel polyamine‑dependent translational mechanism, and a hierarchical framework of translational interventions from prebiotics and probiotics to postbiotics and next‑generation receptor agonists. Collectively, these insights support a hierarchical translational framework from dietary prebiotics and probiotics to standardized postbiotics and next‑generation G‑protein‑coupled receptors agonists as a complement to existing anti‑OP pharmacotherapy. Key knowledge gaps include metabolite identification challenges ('metabolic dark matter') and the need for adequately powered clinical trials with bone‑specific endpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
- Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
Zitieren
APA
Chen, F., Sun, J., & Wang, X. (2026). Gut‑bone metabolites: SCFAs, polyamines and microbial metabolomics in osteoporosis risk and therapy (Review). International Journal of Molecular Medicine, 58(3), 1-21. https://doi.org/10.3892/ijmm.2026.5934
Vancouver
Chen F, Sun J, Wang X. Gut‑bone metabolites: SCFAs, polyamines and microbial metabolomics in osteoporosis risk and therapy (Review). International Journal of Molecular Medicine. 2026;58(3):1-21. doi:10.3892/ijmm.2026.5934
BibTeX
@article{Chen2026,
author = {Chen, Fuchao and Sun, Jingyue and Wang, Xiao},
title = {Gut‑bone metabolites: SCFAs, polyamines and microbial metabolomics in osteoporosis risk and therapy (Review)},
journal = {International Journal of Molecular Medicine},
year = {2026},
volume = {58},
number = {3},
pages = {1--21},
doi = {10.3892/ijmm.2026.5934}
}
EUVIMED